Naloxonazine dihydrochloride 是一种特异性的μ-opioid receptor拮抗剂,IC50为 5.4 nM。Naloxonazine dihydrochloride 也具有抗利什曼原虫活性。
生物活性 | Naloxonazine dihydrochloride is a specificμ-opioid receptorantagonist with anIC50of 5.4 nM. Naloxonazine dihydrochloride also shows anti-leishmanial activity[1][2][3]. |
IC50& Target | μ Opioid Receptor/MOR 5.4 nM (IC50) |
|
体外研究 (In Vitro) | Naloxonazine is relatively stable in solution[2]. Naloxonazine (72 h) is active against the intracellular amastigote stage ofLeishmania donovaniwith a half maximal inhibitory concentration (GI50) of 3.45 μM[3]. Naloxonazine (10 μM; 0-72 h) is active at early stages ofLeishmania donovaniinfection[3]. Naloxonazine affects acidic compartments of the host cell which in turn limitL. donovaniintracellular growth[3].
|
体内研究 (In Vivo) | Naloxonazine (20 mg/kg; i.p.; once) attenuates the increment of locomotor activity induced by acute methamphetamine in mice[1]
Animal Model: | Male ICR mice, methamphetamine (METH)-induced locomotor activity model[1] | Dosage: | 20 mg/kg | Administration: | Intraperitoneal injection, once, 60 min before injecting saline (i.p.) or METH (1 mg/kg, i.p.) | Result: | Significantly attenuated the acute METH-induced increase in locomotor activity and phosphor-Thr75 DARPP-32 levels. |
|
分子量 | |
性状 | |
Formula | |
CAS 号 | |
运输条件 | Room temperature in continental US; may vary elsewhere. |
储存方式 | 4°C, sealed storage, away from moisture *In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture) |